Marketing-authorisation holder
Sandoz Inc.
136 medicines in 1 country, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder
136 medicines in 1 country, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 136
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALKERGOT0.5mg | 1mg · Tablet | Ergoloid mesylates | United States | Not marketed | 1994 |
| ALPHAZINE35mg · Tablet | Phendimetrazine | United States | Not marketed | 1978 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM1gm; 62.5mg base · Tablet, extended release | Amoxicillin, Clavulanic acid | United States | Marketed | 2010 |
| AMPICILLIN SODIUM1gm base/vial | 2gm base/vial · Powder | Ampicillin | United States | Not marketed | 1987 |
| ANECTINE1gm/vial | 20mg/ml | 500mg/vial | 50mg/ml · Injectable | Suxamethonium | United States | Marketed | 1952 |
| ANGIOMAX250mg/vial · Injectable | Bivalirudin | United States | Marketed | 2000 |
| APREPITANT125mg | 40mg | 80mg · Capsule | Aprepitant | United States | Marketed | 2012 |
| ARGATROBAN100mg | 250mg/2.5ml (100mg/ml) | 250mg/250ml | 50mg/50ml (1mg/ml) · Injectable | Argatroban | United States | Marketed | 2000 |
| ARGATROBAN IN DEXTROSE125mg/125ml (1mg/ml) · Solution | Argatroban | United States | Not marketed | 2011 |
| ARRANON250mg/50ml (5mg/ml) · Injectable | Nelarabine | United States | Marketed | 2005 |
| AZOPT1% · Suspension/drops | Brinzolamide | United States | Marketed | 1998 |
| BETOPTIC0.5% base · Solution/drops | Betaxolol | United States | Marketed | 1985 |
| BIMATOPROST0.01% | 0.03% · Solution/drops | Bimatoprost | United States | Marketed | 2015 |
| BRIMONIDINE TARTRATE0.025% | 0.1% | 0.15% | 0.2% · Solution/drops | Brimonidine | United States | Marketed | 2003 |
| CANAGLIFLOZIN100MG | 300mg | 300MG · Tablet | Canagliflozin | United States | Marketed | 2020 |
| CEFADROXIL500mg base · Capsule | Cefadroxil | United States | Marketed | 1980 |
| CEFPODOXIME PROXETIL100mg base | 200mg base · Tablet | Cefpodoxime | United States | Marketed | 2003 |
| CEFPROZIL125mg/5ml | 250mg/5ml · For suspension | Cefprozil | United States | Marketed | 2005 |
| CILOXAN0.3% base · Solution/drops | Ciprofloxacin | United States | Marketed | 1990 |
| CILOXAN0.3% base · Ointment | Ciprofloxacin | United States | Marketed | 1998 |
| CIMERLI0.3mg(6mg/ml) | 0.5mg(10mg/ml) · Injectable | Ranibizumab | United States | Marketed | 2022 |
| CIMETIDINE100mg | 200mg | 300mg | 400mg | 800mg · Tablet | Cimetidine | United States | Marketed | 1994 |
| CIPRO HC0.2% base; 1% · Suspension/drops | Ciprofloxacin, Hydrocortisone | United States | Marketed | 1998 |
| CIPRODEX0.3%; 0.1% · Suspension/drops | Ciprofloxacin, Dexamethasone | United States | Marketed | 2003 |
| CLARITHROMYCIN125mg/5ml | 250mg/5ml · For suspension | Clarithromycin | United States | Marketed | 2007 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 136 | 120 | 16 | CompaniesAll medicines |
Also in the registers of Brazil
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.